Dlamini, J Nomthandazo <br/><br/>
Genotypic resistance at viral rebound among patients who received lopinavir/ritonavir-based or efavirenz-based first antiretroviral therapy in South Africa.  [electronic resource] 

 -  Journal of acquired immune deficiency syndromes (1999)  Nov 2011 
 - 304-8 p.  digital 
<br/><br/> Publication Type: Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S. 
<br/><br/><label>ISSN: </label>1944-7884 
<br/><br/><label>Standard No.: </label>10.1097/QAI.0b013e3182278c29  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Alkynes<br/>Anti-HIV Agents--administration & dosage<br/>Antiretroviral Therapy, Highly Active--methods<br/>Benzoxazines--administration & dosage<br/>Cyclopropanes<br/>Drug Resistance, Viral<br/>Female<br/>HIV Infections--drug therapy<br/>Humans<br/>Lopinavir--administration & dosage<br/>Male<br/>Mutation<br/>RNA, Viral--blood<br/>Ritonavir--administration & dosage<br/>South Africa<br/>Treatment Failure<br/>Viral Load